Nuclear estrogen receptor β in lung cancer:: Expression and survival differences by sex
Nuclear estrogen receptor β in lung cancer:: Expression and survival differences by sex
复制标题
DOI：
10.1158/1078-0432.ccr-05-0498
复制
发表时间：
2005-10-15
影响因子：
11.5
通讯作者：
Brooks, S
中科院分区：
文献类型：
--
作者：
Schwartz, AG;Prysak, GM;Brooks, S
目的：雌激素在决定肺癌风险和预后中的作用是由报道的易感性和生存率的性别差异所提出的。档案肺组织进行了评价的存在下，核雌激素受体（ER）-α和ER-β和ER的状态，受试者的特点，和survival.Experimental Design之间的关系：石蜡包埋的肺肿瘤样本从214名妇女和64名男子从两个人口为基础的，病例对照研究，是10个正常的肺尸检样本的患者没有癌症。通过免疫组织化学测定细胞核ER-α和ER-β表达。Logistic回归被用来确定与ER阳性相关的因素和考克斯比例风险模型被用来衡量生存差异ER status.Results：无论是肿瘤（0的94），也不是正常（0的10）肺组织染色阳性ER-α。61%的肿瘤组织样本（170/278;男性70.3%，女性58.3%）和20%的正常组织样本（2/10; P = 0.01）中存在核ER-β阳性。在多变量分析中，女性患ER-β阳性肿瘤的可能性比男性低46%（比值比，0.54; 95%置信区间，0.27-1.08）。这种关系在腺癌中更强，具有统计学意义（比值比，0.40; 95%置信区间，0.18-0.89）。女性ER阳性肿瘤有一个不显着的73%（P = 01）的死亡率增加，而男性ER-β阳性肿瘤有一个显着的55%（P = 0.04）减少死亡率与ER-β-negative tumors.Conclusions相比：这项研究表明，性别差异表达和影响男性的核ER-β在肺癌，特别是腺癌的生存。
Purpose: A role for estrogens in determining lung cancer risk and prognosis is suggested by reported sex differences in susceptibility and survival. Archival lung tissue was evaluated for the presence of nuclear estrogen receptor (ER) -alpha and ER-beta and the relationship between ER status, subject characteristics, and survival.Experimental Design: Paraffin-embedded lung tumor samples were obtained from 214 women and 64 men from two population-based, case-control studies as were 10 normal lung autopsy samples from patients without cancer. Nuclear ER-alpha and ER-beta expression was determined by immunohistochemistry. Logistic regression was used to identify factors associated with ER positivity and Cox proportional hazards models were used to measure survival differences by ER status.Results: Neither tumor (0 of 94) nor normal (0 of 10) lung tissue stained positive for ER-alpha. Nuclear ER-beta positivity was present in 61% of tumor tissue samples (170 of 278; 70.3% in men and 58.3% in women) and 20% of normal tissue samples (2 of 10; P = 0.01). In multivariate analyses, females were 46% less likely to have ER-beta-positive tumors than males (odds ratio, 0.54; 95% confidence interval, 0.27-1.08). This relationship was stronger and statistically significant in adenocarcinomas (odds ratio, 0.40; 95% confidence interval, 0.18-0.89). Women with ER- positive tumors had a nonsignificant 73% (P = 01) increase in mortality, whereas men with ER-beta-positive tumors had a significant 55% (P = 0.04) reduction in mortality compared with those with ER-beta-negative tumors.Conclusions: This study suggests differential expression by sex and influence on survival in men of nuclear ER-beta in lung cancer, particularly in adenocarcinomas.